v3.26.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Mar. 31, 2024
Cash flows from operating activities      
Net loss $ (505,606) $ (413,840) $ (259,336)
Adjustments to reconcile net loss to net cash used in operating activities:      
Stock-based compensation 55,724 49,487 41,116
Depreciation on property and equipment 409 377 231
Non-cash lease expense 99 133 1,130
Changes in operating assets and liabilities:      
Accounts receivable 986 3,232 (4,577)
Prepaid expenses and other current assets 8,844 (26,990) 1,558
Income tax receivable (2,386) (261) 19
Other assets 69 (7,736) 0
Accounts payable (10,252) 10,684 5,784
Accrued expenses 45,000 8,923 1,349
Operating lease liabilities (99) (138) (1,172)
Due to Roivant Sciences Ltd. (98) 255 (329)
Net cash used in operating activities (407,310) (375,874) (214,227)
Cash flows from investing activities      
Purchases of property and equipment (8) (759) (360)
Net cash used in investing activities (8) (759) (360)
Cash flows from financing activities      
Proceeds from issuance of common stock upon underwritten offering, net of underwriter discounts and commissions, and private placement 544,194 450,000 472,745
Payment of offering and private placement costs (504) (319) (6,012)
Proceeds from stock options exercised 52,066 4,811 5,694
Net cash provided by financing activities 595,756 454,492 472,427
Effect of exchange rate changes on cash and cash equivalents (299) 747 993
Net change in cash and cash equivalents 188,139 78,606 258,833
Cash and cash equivalents – beginning of period 713,971 635,365 376,532
Cash and cash equivalents – end of period 902,110 713,971 635,365
Non-cash operating activity      
Operating lease right-of-use assets obtained in exchange for operating lease liabilities 73 98 91
Supplemental disclosure of cash paid:      
Income taxes $ 2,386 $ 1,202 $ 509

Source